title: Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene.
abstract: It is likely that human genetic differences mediate susceptibility to viral infection and virus-triggered disorders. OAS genes encoding the antiviral enzyme 2',5'-oligoadenylate synthetase (2'5'AS) are critical components of the innate immune response to viruses. This enzyme uses adenosine triphosphate in 2'-specific nucleotidyl transfer reactions to synthesize 2',5'-oligoadenylates, which activate latent ribonuclease, resulting in degradation of viral RNA and inhibition of virus replication. We showed elsewhere that constitutive (basal) activity of 2'5'AS is correlated with virus-stimulated activity. In the present study, we asked whether constitutive activity is genetically determined and, if so, by which variants. Analysis of 83 families containing two parents and two children demonstrated significant correlations between basal activity in parent-child pairs (P<.0001) and sibling pairs (P=.0044), but not spousal pairs, suggesting strong genetic control of basal activity. We next analyzed association between basal activity and 15 markers across the OAS gene cluster. Significant association was detected at multiple markers, the strongest being at an A/G single-nucleotide polymorphism at the exon 7 splice-acceptor site (AG or AA) of the OAS1 gene. At this unusual polymorphism, allele G had a higher gene frequency in persons with high enzyme activity than in those with low enzyme activity (0.44 vs. 0.20; P=3 x 10(-11)). Enzyme activity varied in a dose-dependent manner across the GG, GA, and AA genotypes (tested by analysis of variance; P=1 x 10(-14)). Allele G generates the previously described p46 enzyme isoform, whereas allele A ablates the splice site and generates a dual-function antiviral/proapoptotic p48 isoform and a novel p52 isoform. This genetic polymorphism makes OAS1 an excellent candidate for a human gene that influences host susceptibility to viral infection.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Vagn
authors.initials: V
authors.lastname: Bonnevie-Nielsen
authors.forename: L Leigh
authors.initials: LL
authors.lastname: Field
authors.forename: Shao
authors.initials: S
authors.lastname: Lu
authors.forename: Dong-Jun
authors.initials: DJ
authors.lastname: Zheng
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Pia M
authors.initials: PM
authors.lastname: Martensen
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Nielsen
authors.forename: Henning
authors.initials: H
authors.lastname: Beck-Nielsen
authors.forename: Yu-Lung
authors.initials: YL
authors.lastname: Lau
authors.forename: Flemming
authors.initials: F
authors.lastname: Pociot
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000235:genetics*; D000595:Amino Acid Sequence; D001483:Base Sequence; D005260:Female; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D020641:Polymorphism, Single Nucleotide; D022821:RNA Splice Sites / Q000235:genetics*
chemical_list: D022821:RNA Splice Sites; D015088:2',5'-Oligoadenylate Synthetase
references.citation: Clin Immunol. 2000 Jul;96(1):11-8
references.pmid: 10873423
references.citation: Diabetes. 2005 May;54(5):1588-91
references.pmid: 15855350
references.citation: Eur J Immunogenet. 2000 Jun;27(3):111-7
references.pmid: 10940077
references.citation: Cell Mol Life Sci. 2000 Oct;57(11):1593-612
references.pmid: 11092454
references.citation: Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):143-56
references.pmid: 11325598
references.citation: J Biol Chem. 2001 Jul 6;276(27):25447-55
references.pmid: 11323417
references.citation: Annu Rev Microbiol. 2001;55:255-81
references.pmid: 11544356
references.citation: Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9322-7
references.pmid: 12080145
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11311-6
references.pmid: 12186974
references.citation: Nat Genet. 2002 Dec;32(4):581-3
references.pmid: 12415269
references.citation: Scand J Immunol. 2002 Dec;56(6):630-41
references.pmid: 12472676
references.citation: Biochemistry. 2003 Feb 25;42(7):1805-12
references.pmid: 12590567
references.citation: J Mol Biol. 2003 Mar 7;326(5):1449-61
references.pmid: 12595257
references.citation: Immunol Cell Biol. 2003 Jun;81(3):230-6
references.pmid: 12752688
references.citation: Genes Immun. 2003 Sep;4(6):411-9
references.pmid: 12944978
references.citation: Cancer Res. 2003 Oct 15;63(20):6795-801
references.pmid: 14583476
references.citation: Mol Cell. 2003 Nov;12(5):1173-85
references.pmid: 14636576
references.citation: Diabetes. 1989 Dec;38(12):1636-42
references.pmid: 2573556
references.citation: Diabetes. 1995 Jun;44(6):652-7
references.pmid: 7789630
references.citation: Lancet. 1997 Jan 25;349(9047):236-40
references.pmid: 9014910
references.citation: J Infect Dis. 1997 Mar;175(3):554-60
references.pmid: 9041325
references.citation: J Biol Chem. 1997 Dec 26;272(52):33220-6
references.pmid: 9407111
references.citation: J Med Virol. 1998 Sep;56(1):74-8
references.pmid: 9700636
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8
references.pmid: 9861020
references.citation: Hepatology. 1999 Apr;29(4):1248-51
references.pmid: 10094971
references.citation: Diabetes. 2000 Aug;49(8):1314-8
references.pmid: 10923631